Literature DB >> 20871627

Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.

Weijuan Gong1, Weiming Xiao, Li Qian, Chunxiang Gong, Maozhi Hu, Xianyuan Pan, Mingchun Ji.   

Abstract

Major histocompatibility complex (MHC) class I chain-related protein A (MICA), which is a ligand for human NKG2D, is expressed by a variety of epithelial tumor cells and promotes the activation of natural killer (NK), CD8(+) and γδ-T cells. Although ectopic expression of MICA on tumor cells elicits anti-tumor responses, soluble MICA downregulates the activities of lymphocytes. In this study, we showed that recombinant, immobilized MICA (iMICA) molecules coated on plastic wells weakly promote peripheral NK cell activation, secretion of interferon (IFN)-γ and degranulation without inducing apoptosis. In addition, iMICA synergized with IL-15 and soluble 4-1BB ligand (s4-1BBL) to expand NK cells 25- to 42-fold in a 13-day culture, whereas NK cells stimulated only with IL-15 and s4-1BBL expanded 10- to 16-fold. In contrast to NK cells expanded by IL-15 and s4-1BBL stimulation, NK cells expanded long term in the presence of iMICA exhibited increased cytotoxicity against leukemia cells. These results suggest that large numbers of NK cells with high cytotoxicity can be generated by stimulation with IL-15 and s4-1BBL in the presence of iMICA and that these cells can be used for adoptive cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20871627      PMCID: PMC4002957          DOI: 10.1038/cmi.2010.41

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  27 in total

1.  NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment.

Authors:  A I Roberts; L Lee; E Schwarz; V Groh; T Spies; E C Ebert; B Jabri
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

2.  Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction.

Authors:  Grazia Maria Spaggiari; Paola Contini; Alessandra Dondero; Roberta Carosio; Francesco Puppo; Francesco Indiveri; Maria Raffaella Zocchi; Alessandro Poggi
Journal:  Blood       Date:  2002-07-18       Impact factor: 22.113

3.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.

Authors:  Veronika Groh; Jennifer Wu; Cassian Yee; Thomas Spies
Journal:  Nature       Date:  2002-10-17       Impact factor: 49.962

4.  Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo.

Authors:  A Cerwenka; J L Baron; L L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

Review 5.  New directions in natural killer cell-based immunotherapy of human cancer.

Authors:  Sherif S Farag; Todd A Fehniger; Brian Becknell; Bradley W Blaser; Michael A Caligiuri
Journal:  Expert Opin Biol Ther       Date:  2003-04       Impact factor: 4.388

6.  Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily.

Authors:  Grazia Maria Spaggiari; Paola Contini; Roberta Carosio; Marica Arvigo; Massimo Ghio; Daniela Oddone; Alessandra Dondero; Maria Raffaella Zocchi; Francesco Puppo; Francesco Indiveri; Alessandro Poggi
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

7.  A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.

Authors:  S Carlens; M Gilljam; B J Chambers; J Aschan; H Guven; H G Ljunggren; B Christensson; M S Dilber
Journal:  Hum Immunol       Date:  2001-10       Impact factor: 2.850

8.  Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

Authors:  Ekaterina S Doubrovina; Mikhail M Doubrovin; Elena Vider; Richard B Sisson; Richard J O'Reilly; Bo Dupont; Yatin M Vyas
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

Review 9.  Role of 4-1BB:4-1BB ligand in cancer immunotherapy.

Authors:  Adam T C Cheuk; Ghulam J Mufti; Barbara-ann Guinn
Journal:  Cancer Gene Ther       Date:  2004-03       Impact factor: 5.987

10.  Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.

Authors:  Pascale André; Roberta Castriconi; Marion Espéli; Nicolas Anfossi; Tiffany Juarez; Sophie Hue; Holli Conway; François Romagné; Alessandra Dondero; Marina Nanni; Sophie Caillat-Zucman; David H Raulet; Cristina Bottino; Eric Vivier; Alessandro Moretta; Pascale Paul
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

View more
  3 in total

1.  Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Authors:  Holbrook E Kohrt; Roch Houot; Kipp Weiskopf; Matthew J Goldstein; Ferenc Scheeren; Debra Czerwinski; A Dimitrios Colevas; Wen-Kai Weng; Michael F Clarke; Robert W Carlson; Frank E Stockdale; Joseph A Mollick; Lieping Chen; Ronald Levy
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

2.  Targeting CD137 enhances the efficacy of cetuximab.

Authors:  Holbrook E Kohrt; A Dimitrios Colevas; Roch Houot; Kipp Weiskopf; Matthew J Goldstein; Peder Lund; Antonia Mueller; Idit Sagiv-Barfi; Aurelien Marabelle; Ruth Lira; Emily Troutner; Lori Richards; Amanda Rajapaska; Jonathan Hebb; Cariad Chester; Erin Waller; Anton Ostashko; Wen-Kai Weng; Lieping Chen; Debra Czerwinski; Yang-Xin Fu; John Sunwoo; Ronald Levy
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

3.  Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells.

Authors:  Michael J McNamara; Melissa J Kasiewicz; Stefanie N Linch; Christopher Dubay; William L Redmond
Journal:  J Immunother Cancer       Date:  2014-09-16       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.